On Sept. 19, 2024, the nonprofit organization Focus on Lyme and Aces Diagnostics announced a breakthrough in Lyme disease diagnosis with a new test that detects the disease at all stages including the crucial first 14 days post-infection, with over 90% accuracy. Aces Diagnostics is developing and manufacturing the test, aiming for FDA clearance to make it accessible to all patients.

The Centers for Disease Control and Prevention (CDC) reported that nearly 500,000 people in the U.S. are diagnosed with Lyme disease each year. Globally, 14.5% of the population is affected, with many suffering from chronic symptoms due to delayed diagnosis.